124 related articles for article (PubMed ID: 38112555)
1. Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve.
Chamani IJ; Gannon A; Connell PT; Bisen A; Kovanci E; Sangi-Haghpeykar H; Woodard T; McKenzie LJ
J Adolesc Young Adult Oncol; 2024 Jun; 13(3):465-468. PubMed ID: 38112555
[No Abstract] [Full Text] [Related]
2. Evaluation of ovarian reserve before and after chemotherapy.
Berjeb KK; Debbabi L; Braham M; Zemni Z; Chtourou S; Hannachi H; Hamdoun M; Ayadi M; Kacem K; Zhioua F; Fadhlaoui A; Bahri O; Chakroun N
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102035. PubMed ID: 33307239
[TBL] [Abstract][Full Text] [Related]
3. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
[TBL] [Abstract][Full Text] [Related]
4. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
6. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
7. The protective effect of vitamin D on ovarian reserve and anti-mullerian hormone in patients undergoing chemotherapy for breast cancer, a randomized phase ΙΙ clinical trial.
Dastmardi Z; Lashkari M; Saeedian A; Aghili M; Alipour S
Cancer Rep (Hoboken); 2024 Jun; 7(6):e2104. PubMed ID: 38925607
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
9. Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.
Zhou B; Kwan B; Desai MJ; Nalawade V; Ruddy KJ; Nathan PC; Henk HJ; Murphy JD; Whitcomb BW; Su HI
Fertil Steril; 2022 May; 117(5):1047-1056. PubMed ID: 35216831
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
Goldfarb SB; Turan V; Bedoschi G; Taylan E; Abdo N; Cigler T; Bang H; Patil S; Dickler MN; Oktay KH
Breast Cancer Res Treat; 2021 Jan; 185(1):165-173. PubMed ID: 32930927
[TBL] [Abstract][Full Text] [Related]
11. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
12. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
13. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
14. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
15. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
Luo W; Mao P; Zhang L; Chen X; Yang Z
Ann Palliat Med; 2020 Mar; 9(2):207-215. PubMed ID: 32156138
[TBL] [Abstract][Full Text] [Related]
16. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
18. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
19. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Lambertini M; Ceppi M; Anderson RA; Cameron DA; Bruzzone M; Franzoi MA; Massarotti C; El-Abed S; Wang Y; Lecocq C; Nuciforo P; Rolyance R; Pusztai L; Sohn J; Latocca MM; Arecco L; Pistilli B; Ruddy KJ; Ballestrero A; Del Mastro L; Peccatori FA; Partridge AH; Saura C; Untch M; Piccart M; Di Cosimo S; de Azambuja E; Demeestere I
J Natl Compr Canc Netw; 2023 Jan; 21(1):33-41.e16. PubMed ID: 36634607
[TBL] [Abstract][Full Text] [Related]
20. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Hudis C; Seidman A; Baselga J; Raptis G; Lebwohl D; Gilewski T; Moynahan M; Sklarin N; Fennelly D; Crown JP; Surbone A; Uhlenhopp M; Riedel E; Yao TJ; Norton L
J Clin Oncol; 1999 Jan; 17(1):93-100. PubMed ID: 10458222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
